Azophenols as ERG oncogene inhibitors
AssigneeThe Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
InventorsAlbert L. Dobi, Clifton L. Dalgard, Shiv K. Srivastava
Life of this patent
Estimating the term…
Abstract
Selective azophenol inhibitors of a wild type or an altered ERG protein expression are described, where the inhibitors represent a compound of Formula (I) or Formula (II) wherein X, X1, X2, X3, X4 and X5, R1 through R4 and R9 are as described.
Claims18
A method for treating a disease associated with overexpression of wild type ERG protein, an altered ERG protein, ERG gene transcription or ERG mRNA translation selected from the group consisting of prostate cancer and colon cancer in a subject suffering therefrom, comprising administering to the subject a therapeutically effective amount of a compound selected from the group consisting of Compounds 1-7:
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.